Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12499167 | 1.00 | NPC1 (0.31) | NPC1RAB9AKMT2AMAPTHPGD | |
| SCHEMBL15377658 | 0.80 | NPC1 (0.32) | NPC1RAB9AMAPT | |
| SCHEMBL15377655 | 0.80 | NPC1 (0.32) | NPC1RAB9AMAPT | |
| SCHEMBL10092914 | 0.74 | MAPT (0.40) | KMT2AMAPTHPGD | |
| SCHEMBL14990333 | 0.74 | MAPT (0.40) | KMT2AMAPTHPGD | |
| SCHEMBL14990334 | 0.74 | MAPT (0.40) | KMT2AMAPTHPGD | |
| SCHEMBL12499446 | 0.74 | CCNA2 (0.35) | NPC1RAB9AKMT2AMAPT | |
| SCHEMBL12498348 | 0.74 | POLB (0.47) | NPC1RAB9AKMT2AMAPT | |
| SCHEMBL12499450 | 0.74 | CCNA2 (0.35) | NPC1RAB9AKMT2AMAPT | |
| SCHEMBL12498347 | 0.74 | POLB (0.47) | NPC1RAB9AKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668188-B1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-05-18 | — | — | EP | disclosed |
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| EP-2668188-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-12-04 | — | — | EP | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101029-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDK1, MAP3K1, MAP3K20 | NPC1 1192/4885RAB9A 1090/4885KMT2A 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.